valu usd unless otherwis note
faster growth await rais price target
view product approv brighten prospect
medic devic addit alr launch alin diagnost
platform market growth establish pharmaceut
recoveri pediatr nutrit growth driver
price target move
analysi indic organ revenu growth exceed
bar nutrit three segment medic devic
diagnost establish pharmaceut abt ww
revenu grow collect least face challeng
market condit adult pediatr nutrit revenu flat
year-over-year first nine month depend upon
extent recoveri nutrit estim consolid ww revenu
growth fall exclud alr
product product approv provid impetu faster
growth medic devic major devic
develop stj justifi rational transact
close year ago among signific approv
mr-condit icd mr-condit crt-d
receiv approv mr-condit pacemak
februari rhythm manag account
medic devic revenu biggest drag segment
sale growth sale fell first nine month year
diabet fda approv launch libr acceler
diabet sale
shape excit year diagnost well
close alr transact accret ep
estim enhanc presenc point-of-car diagnost
receiv fda approv first two instrument new alin
platform laboratori diagnost other
forthcom come month alin suit gain good
earli traction europ instrument commerci
rais price target prefer add pullback given
stock strong perform past six month top
pick price target resembl mani way
similar organ revenu ep growth rate least
earli stage new product cycl diversifi
unlik pay dividend compani increas
year like abt fundament stock core
hold medic suppli devic investor howev given
stock out-performance past six month driven fda
approv mri compliant icd libr alin close aler
prefer buy pullback revis price target impli
price-to-earnings multipl ep y/i
price prior trade day market close estimate unless otherwis note
medic
devic bar rhythm manag product
categori deliv higher revenu growth rel
perform recent potenti product
approv rhythm manag mr-condit icds/
crt-d pacemak reduc even elimin
drag product categori
earli success alin system core
diagnost europ bode potenti
launch diagnost growth outsid benefit
launch new suit instrument share
alin platform instrument expect becom
avail
estim accret alr may
conserv ep estim assum
accret alr manag share
forecast alr accret issu guidanc
januari estim earn power next year least
provid potenti near-term regulatori
approv receiv time
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-part
analysi valu report segment individu base
peer group multipl blend ev/ebitda multipl
ebitda estim billion yield
target key assumpt underli valuat
mid single-digit cc organ revenu growth
basi point increas oper margin
year addit debt reduct beyond
contempl manag guidanc price target
impli price-to-earnings multipl ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key
differ base-cas assumpt mid
high single-digit cc organ revenu growth
basi point ebit margin expans year
due higher revenu growth faster realiz cost
synergi integr stj alr faster debt
downsid scenario ebitda
billion key differ base-cas assumpt
low mid single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
diabet establish pharmaceut multipl along
ebitda estim busi give blend ev/ebitda estim
consolid ebitda billion target impli multipl
ep estim peer group evebitda price-to-earnings multipl large-cap med-tech
compani consensu estim price target basi
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
